Prognostic and Long-term Survival of Immune Thrombotic Thrombocytopenic Purpura in older patients.

Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment.

Loss of von Willebrand factor high-molecular-weight multimers at acute phase is associated with detectable anti-ADAMTS13 IgG and neurological symptoms in acquired thrombotic thrombocytopenic purpura.

Rituximab Prevents Stroke Recurrences in Atypical Chronic Immune-Mediated Thrombotic Thrombocytopenic Purpura.

Impact of hypertensive emergency and complement rare variants on presentation and outcome of atypical hemolytic uremic syndrome.

Transfer of ADAMTS13 antibodies-mediated thrombotic thrombocytopenic purpura via kidney transplantation.

Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine.

Post-partum acute kidney injury: sorting placental and non-placental thrombotic microangiopathies using the trajectory of biomarkers
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.

Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients.

Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort.

ADAMTS13 Gene Mutations Influence ADAMTS13 Conformation and Disease Age-Onset in the French Cohort of Upshaw-Schulman Syndrome.

Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura.

Early differenciation of shiga-toxin-associated hemolytic uremic syndrome in critically ill adults with thrombotic microangiopathy syndromes.

Pediatric thrombotic thrombocytopenic purpura.

Eculizumab for catastrophic antiphospholipid syndrome-a case report and literature review.

Early Differentiation of Shiga Toxin-Associated Hemolytic Uremic Syndrome in Critically Ill Adults With  Thrombotic

Increased Fatty Acid Oxidation in Differentiated Proximal Tubular Cells Surviving a Reversible Episode of Acute Kidney Injury.

Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome.
Microangiopathy Syndromes.

Urinary transcriptomics reveals patterns associated with subclinical injury of the renal allograft.

Urinary mRNA analysis of biomarkers to epithelial mesenchymal transition of renal allograft.

French Network of systemic and immune disorders associated with hemopathies and cancer (MINHEMON). Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study.

Thrombotic thrombocytopenic purpura. Joly BS et al. Blood 2017 May 25; 129(21): 2836-2846.

Thrombotic thrombocytopenic purpura. Kremer Hovinga JA et al. Nat Rev Dis Primers. 2017 Apr 6;3:17020.

The ADAMTS131239-1253 peptide is a dominant HLA-DR1-restricted CD4+ T-cell epitope. Gilardin L et al. Haematologica. 2017 Jul 27. pii: haematol.2015.136671.

Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: Causes of diagnostic errors and consequence on outcome. Experience of the French thrombotic microangiopathies reference centre. Grall M et al. Am J Hematol. 2017 Apr;92(4):381-387.

Predictive features of chronic kidney disease in atypical haemolytic uremic syndrome. Jamme M et al. PLoS One. 2017 May 18;12(5):e0177894.

Understanding therapeutic targets in thrombotic thrombocytopenic purpura. Joly BS et al. Intensive Care Medicine 2017
Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. Scully M et al. J Thromb Haemost 2016
Assessment of endothelial damage and cardiac injury in a mouse model mimicking thrombotic thrombocytopenic purpura. Le Besnerais M et al. J Thromb Haemost 2016
Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathies. Joly BS et al. Lancet Haematology 2016
Efficacy of rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative study. Benhamou Y et al. Am J Hematol 2016

Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange.
Twice-daily therapeutical plasma exchange-based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.
Risk Factors for Autoimmune Diseases Development After Thrombotic Thrombocytopenic Purpura.
Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story.
Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study.
Incidence of obstetrical thrombotic thrombocytopenic purpura in a retrospective study within thrombocytopenic pregnant women. A difficult diagnosis and a treatable disease.
Are platelet transfusions harmful in acquired thrombotic thrombocytopenic purpura at the acute phase? Experience of the French thrombotic microangiopathies reference center.
Platelet transfusion and catheter insertion for plasma exchange in patients with thrombotic thrombocytopenic purpura and a low platelet count.
Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC.
Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center.